Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy

Inclusion Criteria: * Patient of both sexes age 18 or above * Biopsy-proven IgA nephropathy * Baseline serum creatinine ≥ 1.2mg/dl(Female),≥ 1.4mg/dl(Male) * Able to give written informed consent Exclusion Criteria: * Hypertension SBP\>160mmHg and/or DBP\>100mmHg * Subject, who in the investigator's opinion, has a systemic disease that would contraindicate participation in this study * Use of omega-3 fatty acids or analog supplement * Pregnancy or breast feeding at time of entry or unwillingness to comply with measures for contraception * Current or recent (within 30 days) exposure to any investigational drug * Subject who has hypersensitivity to this agent as a previous illness * Low platelet(\<100,000/㎕) or the subject who has a high risk of bleeding * Use of corticosteroid during the treatment period or less than 3 months prior to the screening * Use of anticoagulant during the treatment period or within 1 month or 6 half lives prior to screening * Subject who in the investigator's opinion, would be confronted with a difficulty